Velcade-melphalan-prednisone
Showing 1 - 25 of 1,641
Multiple Myeloma Trial in Torino (velcade subcutaneous melphalan prednisone, velcade cyclophosphamide prednisone, velcade
Active, not recruiting
- Multiple Myeloma
- velcade subcutaneous melphalan prednisone
- +2 more
-
Torino, ItalyA.O.U. Città della Salute e della Scienza di Torino - SC Ematolo
Mar 24, 2022
Multiple Myeloma Trial in Torino (Bortezomib, Melphalan, Prednisone, Thalidomide, Bortezomib, Melphalan, Prednisone)
Completed
- Multiple Myeloma
- Bortezomib, Melphalan, Prednisone, Thalidomide
- Bortezomib, Melphalan, Prednisone
-
Torino, ItalyA.O.U. S. Giovanni Battista
Dec 22, 2020
Multiple Myeloma Trial in Torino (Velcade, Melphalan, Prednisone)
Recruiting
- Multiple Myeloma
- Velcade
- +5 more
-
Torino, TO, ItalyDipartimento di Biotecnologie Molecolari e Scienze per la Salute
May 25, 2022
Multiple Myeloma Trial in France, Spain, United States (Daratumumab, Velcade, Pomalidomide)
Active, not recruiting
- Multiple Myeloma
- Daratumumab
- +11 more
-
Duarte, California
- +21 more
Jan 17, 2023
Multiple Myeloma Trial (RP followed by MPR)
Active, not recruiting
- Multiple Myeloma
- RP followed by MPR
- (no location specified)
Mar 24, 2022
Multiple Myeloma, Newly Diagnosed Patients Trial in Torino (Melphalan, Lenalidomide, Prednisone)
Active, not recruiting
- Multiple Myeloma
- Newly Diagnosed Patients
- Melphalan
- +2 more
-
Torino, ItalyDivision of Hematology, AOU Città della Salute e della Scienza d
Mar 24, 2022
Multiple Myeloma Trial in Torino (Melphalan, Prednisone, Lenalidomide, Cyclophosphamide, Prednisone, Lenalidomide, Lenalidomide,
Active, not recruiting
- Multiple Myeloma
- Melphalan, Prednisone, Lenalidomide
- +2 more
-
Torino, TO, ItalyDivision Of Hematology, A.O.U. Città della Salute e della Scienz
Mar 24, 2022
Multiple Myeloma, Auto Stem Cell Transplant Trial in Hackensack (Bortezomib)
Active, not recruiting
- Multiple Myeloma
- Auto Stem Cell Transplant
-
Hackensack, New JerseyJohn Theurer Cancer Center @ Hackensack University Medical Cente
Dec 23, 2022
Multiple Myeloma Trial (Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT
Not yet recruiting
- Multiple Myeloma
- Dara-VRd intensification, Dara-R maintenance
- +4 more
- (no location specified)
Dec 13, 2022
Primary Systemic Amyloidosis, Light Chain Deposition Disease Trial in United States (drug, genetic, other, procedure)
Active, not recruiting
- Primary Systemic Amyloidosis
- Light Chain Deposition Disease
- bortezomib
- +6 more
-
Denver, Colorado
- +6 more
Aug 24, 2022
Multiple Myeloma Trial in Hackensack (Fludarabine monophosphate, melphalan, Bortezomib)
Completed
- Multiple Myeloma
- Fludarabine monophosphate, melphalan, Bortezomib
-
Hackensack, New JerseyJohn Theurer Cancer Center at Hackensack University Medical Cent
Apr 29, 2022
Multiple Myeloma Trial in Vitoria-Gasteiz (Bortezomib, Melphalan, Prednisone)
Terminated
- Multiple Myeloma
- Bortezomib
- +2 more
-
Vitoria-Gasteiz, Araba, SpainAraba of University Hospital
Jan 14, 2020
Multiple Myeloma Trial in Washington, Hackensack (Melphalan, Bortezomib)
Active, not recruiting
- Multiple Myeloma
-
Washington, District of Columbia
- +1 more
May 6, 2022
T-cell Non-Hodgkin Lymphoma Trial in Boston (Cyclophosphamide, Doxorubicin, Vincristine)
Terminated
- T-cell Non-Hodgkin Lymphoma
- Cyclophosphamide
- +12 more
-
Boston, Massachusetts
- +1 more
Jan 26, 2023
Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma Trial in Wuhan (Daratumumab, Carfilzomib,
Recruiting
- Multiple Myeloma
- +2 more
- Daratumumab
- +10 more
-
Wuhan, Hubei, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College,
Nov 18, 2023
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia Trial in Duarte (drug,
Active, not recruiting
- Autologous Hematopoietic Stem Cell Transplant Recipient
- +4 more
- bortezomib
- +7 more
-
Duarte, CaliforniaCity of Hope
Mar 17, 2022
Multiple Myeloma Trial in Little Rock (Carfilzomib, Thalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- +11 more
-
Little Rock, ArkansasUniversity of Arkansas for Medical Sciences
Sep 1, 2022
Multiple Myeloma, Refractory Multiple Myeloma Trial (procedure, drug, radiation)
Withdrawn
- Multiple Myeloma
- Refractory Multiple Myeloma
- nonmyeloablative allogeneic hematopoietic stem cell transplantation
- +7 more
- (no location specified)
Jan 4, 2023
Multiple Myeloma Trial in Little Rock (M-VTD-PACE, TT3-LITE Regimen (L-TT3))
Active, not recruiting
- Multiple Myeloma
- M-VTD-PACE
- TT3-LITE Regimen (L-TT3)
-
Little Rock, ArkansasUniversity of Arkansas for Medical Sciences, Myeloma Institute f
Oct 4, 2021
Plasma Cell Myeloma Trial in Israel, United States (Laboratory Biomarker Analysis, Lenalidomide, Melphalan)
Active, not recruiting
- Plasma Cell Myeloma
- Laboratory Biomarker Analysis
- +5 more
-
Mobile, Alabama
- +392 more
Jan 25, 2023
Maintenance With Bortezomib Plus Daratumumab After Induction
Recruiting
- Multiple Myeloma
- Non-eligible for Autologous Stem Cell Transplantation (ASCT)
-
Arganda Del Rey, Spain
- +31 more
Sep 15, 2022
Myeloma Trial in Houston (Trisenox (Arsenic Trioxide), Velcade (Bortezomib), Melphalan)
Completed
- Myeloma
- Trisenox (Arsenic Trioxide)
- +3 more
-
Houston, TexasUT MD Anderson Cancer Center
Sep 1, 2020
Multiple Myeloma Trial in Worldwide (Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib)
Terminated
- Multiple Myeloma
- Melphalan flufenamide (Melflufen)
- +3 more
-
Boston, Massachusetts
- +15 more
Mar 4, 2022
Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune Trial in Denver, Seattle (biological,
Recruiting
- Autoimmune Disease
- +18 more
- Anti-Thymocyte Globulin
- +9 more
-
Denver, Colorado
- +2 more
Feb 1, 2023